Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-23

Study Completion Date

2022-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

NCT03590392

Chikungunya Fever

COMPLETED PHASE1

Phase I Trial of Measles Vectored Chikungungya Vaccine

NCT03028441

Chikungunya Virus Infection

COMPLETED PHASE1

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358

Viral Vaccines Chikungunya Fever Chikungunya Virus Infection

COMPLETED PHASE1

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984

Chikungunya Virus

RECRUITING PHASE3

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

NCT03483961

Chikungunya Virus Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1 Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration, and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12 participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika administered contralaterally. Group 10 will receive placebo in both arms.

Enrolment into this study will be implemented in a step-wise dose escalation manner. Participants will be first recruited into the vaccination groups at the lowest dose (Groups 1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory interim clinical safety reviews that participants will be enrolled into the mid dose groups (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be enrolled last, after completion and interim clinical safety reviews from the mid dose groups. Participants allocated to the Placebo group (Group 10) will be evenly distributed across the dose escalation model.

Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of the four intervention arms.

The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken for 6 months after vaccination day

Innovate UK (project number 971557)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chikungunya Zika

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CHIK low dose

Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK low dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^9 vp ChAdOx1 Chik

CHIK mid dose

Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK mid dose

Intervention Type BIOLOGICAL

A single dose of 2.5x10\^10 vp ChAdOx1 Chik

CHIK high dose

Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK high dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^10 vp ChAdOx1 Chik

ZIKA low dose

Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

ZIKA low dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^9 vp ChAdOx1 Zika

ZIKA mid dose

Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

ZIKA mid dose

Intervention Type BIOLOGICAL

A single dose of 2.5x10\^10 vp ChAdOx1 Zika

ZIKA high dose

Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

ZIKA high dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^10 vp ChAdOx1 Zika

CHIK ZIKA low dose

Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Chik and 5x10\^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK low dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^9 vp ChAdOx1 Chik

ZIKA low dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^9 vp ChAdOx1 Zika

CHIK ZIKA mid dose

Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Chik and 2.5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK mid dose

Intervention Type BIOLOGICAL

A single dose of 2.5x10\^10 vp ChAdOx1 Chik

ZIKA mid dose

Intervention Type BIOLOGICAL

A single dose of 2.5x10\^10 vp ChAdOx1 Zika

CHIK ZIKA high dose

Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Chik and 5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type EXPERIMENTAL

CHIK high dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^10 vp ChAdOx1 Chik

ZIKA high dose

Intervention Type BIOLOGICAL

A single dose of 5x10\^10 vp ChAdOx1 Zika

Placebo

Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator

Group Type PLACEBO_COMPARATOR

Saline placebo

Intervention Type BIOLOGICAL

A single dose of isotonic saline solution (0.9%)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CHIK low dose

A single dose of 5x10\^9 vp ChAdOx1 Chik

Intervention Type BIOLOGICAL

CHIK mid dose

A single dose of 2.5x10\^10 vp ChAdOx1 Chik

Intervention Type BIOLOGICAL

CHIK high dose

A single dose of 5x10\^10 vp ChAdOx1 Chik

Intervention Type BIOLOGICAL

ZIKA low dose

A single dose of 5x10\^9 vp ChAdOx1 Zika

Intervention Type BIOLOGICAL

ZIKA mid dose

A single dose of 2.5x10\^10 vp ChAdOx1 Zika

Intervention Type BIOLOGICAL

ZIKA high dose

A single dose of 5x10\^10 vp ChAdOx1 Zika

Intervention Type BIOLOGICAL

Saline placebo

A single dose of isotonic saline solution (0.9%)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy men aged 18 to 50 (inclusive) years at the time of screening.
2. Healthy women aged 18 to 50 (inclusive) of child-bearing potential who agree to practice continuous effective contraception (see below) during the study and test negative for pregnancy on the day(s) of screening and vaccination.
3. Are residents of the metropolitan area of Monterrey, Nuevo León.
4. Provide written informed consent for participation in the study.
5. Able and willing (in the Investigator's opinion) to comply with all study requirements.
6. Agreement to inform study team of any impending vaccinations either before or during participation in the study.
7. Agreement to refrain from blood donation during the course of the study.
8. Agreement to refrain from receipt of any alphavirus or flavivirus vaccine throughout the duration of the study (e.g. investigational or licensed Yellow Fever, Japanese Encephalitis, Tick Borne Encephalitis or Dengue virus vaccines).

Exclusion Criteria

1. Participation in another clinical trial in the 30 days preceding enrolment or during the study period.
2. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine, Chikungunya virus vaccine, Zika virus vaccine, Dengue virus vaccine).
3. Prior receipt of any vaccines administered ≤30 days before enrolment and/or planned during the during the study.
4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
6. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Any history of anaphylaxis in relation to vaccination.
7. History of autoimmune disease.
8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
9. Pregnancy, lactation or willingness/intention to become pregnant during the study.
10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
11. History of serious psychiatric condition likely to affect participation in the study
12. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
13. Any other serious chronic illness requiring hospital specialist supervision at present or during the last 6 months.
14. Suspected or known current alcohol abuse. For men, intake greater than 5 drinks on a single occasion or more than 15 drinks per week; and for women, more than 4 drinks on a single occasion or more than 8 drinks per week. One drink =14 grams of pure alcohol.
15. Suspected or known injecting drug abuse in the 5 years preceding enrolment.
16. Seropositive for hepatitis B surface antigen (HBsAg).
17. Seropositive for hepatitis C virus (antibodies to HCV).
18. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis.
19. Has history of chronic or acute severe neurologic condition. Including: Neurologic and Neuroinflammatory Disorders: ADEM, including site specific variants, Cranial Nerve Disorders (including paralyses/paresis), GBS (including Miller Fisher Syndrome and other variants), Immune-mediated Peripheral Neuropathies and Plexopathies, Optic Neuritis, Multiple Sclerosis, Narcolepsy, Transverse Myelitis, meningitis, or meningoencephalitis.
20. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
21. Seropositivity or cross-reactivity to Chikungunya virus, Zika virus or Dengue virus on screening tests.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes